BBP-418
Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Phase 3Positive Interim Results
Key Facts
Indication
Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Phase
Phase 3
Status
Positive Interim Results
Company
About BridgeBio Pharma
BridgeBio Pharma operates as a diversified biotech platform targeting genetic diseases through its innovative hub-and-spoke organizational model. The company has advanced multiple programs into Phase 3 trials, including acoramidis for transthyretin amyloidosis, encaleret for hypoparathyroidism, and infigratinib for achondroplasia. With over 2,000 patients enrolled in clinical trials globally and a pipeline consisting of 100% first-in-class or best-in-class therapies, BridgeBio has established itself as a leader in genetic medicine development.
View full company profile